Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deferred Tax Liability (2016 - 2018)

CytomX Therapeutics (CTMX) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $1.1 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2018, changed N/A, and an annual FY2018 reading of $1.1 million, changed N/A over the prior year.
  • Non-Current Deferred Tax Liability was $1.1 million for Q4 2018 at CytomX Therapeutics, up from $520000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $1.1 million in Q4 2018 and bottomed at $499000.0 in Q4 2014.
  • Average Non-Current Deferred Tax Liability over 5 years is $570181.8, with a median of $513000.0 recorded in 2016.
  • Peak annual rise in Non-Current Deferred Tax Liability hit 5.07% in 2017, while the deepest fall reached 0.78% in 2017.
  • Year by year, Non-Current Deferred Tax Liability stood at $499000.0 in 2014, then rose by 1.6% to $507000.0 in 2015, then increased by 1.18% to $513000.0 in 2016, then grew by 1.36% to $520000.0 in 2017, then skyrocketed by 118.65% to $1.1 million in 2018.
  • Business Quant data shows Non-Current Deferred Tax Liability for CTMX at $1.1 million in Q4 2018, $520000.0 in Q3 2017, and $539000.0 in Q2 2017.